These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8463726)

  • 21. [Moxifloxacin--a novel antimicrobial preparation for treatment of respiratory infections].
    Iakovlev SV; Polushkina NR; Iakovlev VP
    Ter Arkh; 2001; 73(11):15-22. PubMed ID: 11806197
    [No Abstract]   [Full Text] [Related]  

  • 22. Adverse drug reactions to fluoroquinolones in pediatric patients in a tertiary care hospital.
    Reeta K; Uppal R; Jhaj R; Malhotra S; Bhargava VK
    Indian J Physiol Pharmacol; 2000 Jan; 44(1):113-4. PubMed ID: 10919107
    [No Abstract]   [Full Text] [Related]  

  • 23. [Ofloxacin in mycobacteriosis therapy].
    Padełskaya EN
    Antibiot Khimioter; 1997; 42(11):26-31. PubMed ID: 9463298
    [No Abstract]   [Full Text] [Related]  

  • 24. Tendons and fluoroquinolones. Unresolved issues.
    Kahn MF; Hayem G
    Rev Rhum Engl Ed; 1997; 64(7-9):437-9. PubMed ID: 9338923
    [No Abstract]   [Full Text] [Related]  

  • 25. [Maxaquin in the combined treatment of tuberculosis].
    Sokolova GB; Mozhokina GN; Kunichan AD; Elistratova NA; Perel'man MI
    Probl Tuberk; 2000; (5):35-9. PubMed ID: 11077850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does the use of fluoroquinolones for the empiric treatment of pneumonia delay initiation of treatment of tuberculosis?
    Abiad H
    Clin Infect Dis; 2002 Dec; 35(12):1572; author reply 1572-3. PubMed ID: 12471582
    [No Abstract]   [Full Text] [Related]  

  • 27. The safety profile of the fluoroquinolones.
    Bertino J; Fish D
    Clin Ther; 2000 Jul; 22(7):798-817; discussion 797. PubMed ID: 10945507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Trovafloxacin].
    Azanza JR; Ollero D; Sádaba B; García Quetglas E
    Rev Med Univ Navarra; 1999; 43(1):45-57. PubMed ID: 10386346
    [No Abstract]   [Full Text] [Related]  

  • 29. [Fluorquinones and tendinitis].
    Schou HS
    Ugeskr Laeger; 1997 Feb; 159(6):784-5. PubMed ID: 9045475
    [No Abstract]   [Full Text] [Related]  

  • 30. [Do some drugs have adverse effects on cartilage?].
    Bertin P; Gillet P; Treves R; Netter P
    Therapie; 1998; 53(1):17-20. PubMed ID: 9773095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial: Strategies Played by Immune Cells and Mycobacteria in the Battle Between Antimicrobial Activity and Bacterial Survival.
    Schmitz V; Jo EK; Ochoa MT; Teles RMB
    Front Immunol; 2022; 13():869692. PubMed ID: 35309365
    [No Abstract]   [Full Text] [Related]  

  • 32. Bayer seeks veterinary, industry backing before Baytril hearing.
    J Am Vet Med Assoc; 2002 May; 220(10):1436, 1438. PubMed ID: 12018362
    [No Abstract]   [Full Text] [Related]  

  • 33. Should children be deprived of the benefits of flouroquinolones?
    de Silva DG
    Ceylon Med J; 1994 Jun; 39(2):113-4. PubMed ID: 7923451
    [No Abstract]   [Full Text] [Related]  

  • 34. [The safety of new quinolone treatment--levoflaxacin (tavanic) and moxiflocacin (megaxin)-- in the community].
    Bolkovshtein M; Lederman N; Berkovitch M
    Harefuah; 2001 Nov; 140(11):1054-7. PubMed ID: 11759381
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of mycobacterial lung diseases in patients without HIV infection].
    Słupek A
    Pneumonol Alergol Pol; 1998; 66(1-2):5-8. PubMed ID: 9658875
    [No Abstract]   [Full Text] [Related]  

  • 36. [Tendinopathies and fluoroquinolones: a public health problem? Value of drug monitoring studies].
    Pierfitte C
    Bull Soc Sci Med Grand Duche Luxemb; 1995; 132(3):39-40. PubMed ID: 8665625
    [No Abstract]   [Full Text] [Related]  

  • 37. Information on adverse drug reaction in cats.
    Davidson M
    J Am Vet Med Assoc; 2001 Dec; 219(12):1676. PubMed ID: 11767912
    [No Abstract]   [Full Text] [Related]  

  • 38. [Preclinical study of therapeutic agents used against Mycobacterium avium complex infections--with special reference to new macrolides and new quinolones].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1996 Sep; 71(9):531-5. PubMed ID: 8999135
    [No Abstract]   [Full Text] [Related]  

  • 39. [The treatment of leprosy].
    Merklen FP; Cottenot F
    Therapeutique; 1973 Apr; 49(4):267-8. PubMed ID: 4775220
    [No Abstract]   [Full Text] [Related]  

  • 40. Non-tuberculous mycobacterial infections in the Scottish Borders.
    Bredin CP
    J R Coll Physicians Edinb; 2012 Mar; 42(1):93. PubMed ID: 22441076
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.